Nuwellis Showcases Aquadex System at AATS Meeting Amid Cardiorenal Focus
Event summary
- Nuwellis to present Aquadex SmartFlow ultrafiltration system at AATS 106th Annual Meeting (May 2–5, Chicago).
- Company will also participate in ERAS Cardiac Spring Retreat for cardiac surgery care discussions.
- CEO John Erb highlights focus on precision ultrafiltration therapy advancements.
The big picture
Nuwellis' participation in high-profile cardiothoracic events underscores its push to solidify market position in fluid management for cardiorenal patients. The focus on precision therapy aligns with broader industry trends toward data-driven, personalized cardiac care solutions. Success hinges on physician adoption and differentiation from established competitors.
What we're watching
- Technology Adoption
- How Nuwellis' precision ultrafiltration messaging resonates with cardiothoracic surgeons at AATS.
- Competitive Positioning
- Whether the company can differentiate Aquadex in a crowded cardiorenal therapy market.
- Regulatory Dynamics
- The pace at which Nuwellis advances its ultrafiltration technology through clinical validation.